Skip to main content



Save the Date for 

Clinical Epigenetics International Conference - CLEPIC 2023

Warsaw Poland, June 05 – 07, 2024 

More information coming soon at

Welcoming words from Lucia Altucci and Marianne Rots, Editors in Chief of Clinical Epigenetics:

The need to meet and greet

Scientists need to meet to stay up-to-date within and beyond one’s own research field, to exchange and fuel new ideas, to keep inspired and to inspire others. Corona-volente, we aim to offer you such platform by bringing together the editors, authors and readers of Clinical Epigenetics as well as the newly launched Epigenetics Communications. Moreover, we will invite industrial partners and public bodies, with a focus on training the next generation of multidisciplinary multi-epiomics scientists. This conference starts a series of annual conferences devoted to fully exploiting the many applications of epigenetics in health and disease as well as in all kingdoms of life (biotech, crop breeding, etc.).

Looking forward to meeting and greeting many of you in a relaxed atmosphere full of state-of-the-art epigenetics!

Call for Papers: Epigenetic Mechanisms in Developmental Origin of Health and Disease

This Collection focuses on the most recent advances in epigenetic research pertaining to Developmental Origins of Health and Disease (DOHaD), including mechanistic, targeted, and genome-wide epigenetic analyses. We encourage submissions encompassing studies focused on epigenetics in DOHaD to increase our understanding of developmental epigenetic plasticity, how it conditions health postnatally, and the possible translation of this knowledge into clinical practice.

EACR Cellular Bases for Patient Response to Cancer Therapies

New Content Item
We are proud to share information about the upcoming meeting:

EACR Cellular Bases for Patient Response to Cancer Therapies
Date & Location: 14 - 16 November 2023 | Lyon, France

This conference will focus on the most recent studies that have uncovered novel molecular pathways involved in response anticancer therapy. A panel of speakers involved in cutting-edge studies on the biological and cellular bases for therapeutic response in cancer will share their vision on how these disruptive discoveries could be exploited to rethink cancer therapies to ultimately improve therapeutics.

Check out Confirmed Speakers here.
Key dates:

Travel grant application deadline: 19 September 2023
Abstract submission deadline: 19 September 2023
Early registration deadline: 17 October 2023

EACR-AstraZeneca Cancer Epigenetics

New Content Item

We are proud to share information about the upcoming meeting:
EACR-AstraZeneca Cancer Epigenetics

Date & Location: 05 – 06 December 2023 | Virtual Event, Worldwide

Epigenetic control is essential for development and differentiation, and this control mechanism is very frequently deregulated in cancer. Several small molecule inhibitors have been developed in recent years that have either been approved for clinical use or are in preclinical and clinical trials. This conference will focus on basic and clinical aspects of targeting a broad panel of epigenetic proteins in cancer, either as monotherapies, or as combination therapies, including the use of immune checkpoint inhibitors to increase drug sensitivity and overcome chemoresistance.

Check out Confirmed Speakers here.

Key dates:
Abstract submission deadline: 09 October 2023

Registration deadline: 13 November 2023

New thematic series: Multiscale chromatin dynamics

New Content ItemWe are proud to announce a new cross-journal thematic series between Epigenetics Communications and Clinical Epigenetics, guest edited by Pernette Verschure and Wim Vanden Berghe. The last few years have seen a wealth of knowledge on the role of epigenetic gene regulation in (patho-)physiological processes. New insights relate to the highly dynamic nature of epigenetic systems. Epigenetic regulatory proteins are in constant motion in the nucleus, exchanging between chromatin-bound and unbound states. In addition,  various layers of chromatin folding show defined dynamics. The causal relationship between these dynamics of chromatin and nuclear organization with gene activity and silencing is still an open question of great importance. Find out more about the scope here.

Find Best-Fit Journal for your article!

Choosing the right journal is essential for every author, and we are fully committed to collaborating across our prestigious epigenetics journals to assist you in this process. To facilitate an informed decision, we offer a concise overview of our three journals. For more detailed information on each one, simply click on the journal title below: Best fit journal

Clinical Epigenetics

Epigenetics & Chromatin 

Epigenetics Communications

Our dedicated Editors, with their extensive expertise in the field, will carefully evaluate your submission. If they believe that another journal within our network may better align with your research, they will propose a transfer during the peer-review process. This transfer will significantly expedite the handling of your submission, eliminating the need for additional peer-review rounds. We value your research and are here to support you every step of the way. Explore our options and make the most of our collaborative efforts to ensure your work reaches its full potential. 

Editorial Policy Regarding Submissions describing “Negative Outcome Studies”

Provided that the methodology is consistent and sound, and the research question brings added value to the field, we warmly welcome ‘negative results’ studies. Manuscripts to be considered include, but are not limited to, descriptions of:

  • (failed) attempts to reproduce previously published data
  • irreproducible data between two (collaborating) laboratories
  • failed, but technically solid, attempts to prove a scientific hypothesis

Manuscripts which will not be considered include:

  • bioinformatic analyses without a solid statistical approach
  • "stand alone" bioinformatic analyses without experimental proof

Editorial Policy Regarding Submissions Focusing on Non-coding RNAs or RNA Modifications

Since epigenetic regulation and associated aspects of transcription regulation are wide-spread and complex, Epigenetics Communications aims to focus on those aspects of ncRNA-induced epigenetic regulation that concern changes in chromatin organization. As such manuscripts on non-coding RNAs or RNA modifications are only acceptable for the journal when including: 

  • data on the molecular epigenetic regulation of the expression of non-coding RNA (or its modifying enzymes) or
  • insights on the mechanism of action of the non-coding RNA on the chromatin and/or functioning of the DNA or
  • insights in mitotic stability of the RNA-induced effect

Editorial Policy Regarding Submissions Focusing on In silico research

Manuscripts reporting on straightforward bioinformatic analyses of publicly accessible databases only, cannot be considered for publication in Epigenetics Communications, unless the manuscript presents:

  • new, convincingly-described, scientific insights which will impact the field and/or
  • additional insights into underlying biological mechanisms (“wet-lab” validations) and/or
  • validations of findings in a replication cohort


Lucia Altucci, Università degli Studi della Campania, Italy
Marianne Rots, University Medical Center Groningen, Netherlands  

Aims and scope

Epigenetics Communications covers the broad spectrum of epigenetic science from basic research to technological and therapeutic innovations, as well as their theoretical, ethical and societal dimensions. Epigenetics Communications is an innovative new, open-access journal devoted to the study and problematization of epigenetic principles and mechanisms in basic and translational research settings. It is also a forum for interdisciplinary debates around epigenetics, as well as for the investigation of its societal dimensions. In support of open science initiatives, the journal will have a level 4 data policy requiring data be made publicly available. The journal is divided into the following sections:

  • Molecular Epigenetics (Histone Modifications; DNA Methylation; DNA Demethylation)
  • Nuclear Organization
  • Mitotic & Meiotic Heritability
  • Epigenetic Drugs
  • Epigenetic Technologies
  • Epigenetic Bioengineering
  • Network Epigenetics
  • Computational Epigenomics
  • Single Cell Epigenetics
  • Epigenetic Toxicology
  • Model Organisms (Vertebrates; Invertebrates; Plants; Unicellular systems)
  • Epigenetics and Society

Epigenetics Communications will support the publication of manuscripts that contribute to a further understanding of epigenetic mechanisms that impact functioning of systems and organisms. Submissions describing clinical applications are referred to the sister journal, Clinical Epigenetics.

This new and innovative journal will also act as a forum to showcase and discuss alternative conclusions/interpretations of well-established epigenetic phenomena. These can be based either on the (re-)analyses of published and/or new data, or on the findings and results of epigenetic research in interaction with other disciplines. As such, we welcome 'systematic’ and ‘critical’ studies, be them positive (expected) or negative (non-expected) with respect to their outcomes.

Annual Journal Metrics

2022 Speed
20 days submission to first editorial decision for all manuscripts (Median)
133 days submission to accept (Median)

2022 Usage 
14 Altmetric mentions